Condition: Fabry Disease · Sponsor: Chiesi Italia
PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.
This description comes directly from the study's public registry record.
Chiesi Clinical Trial info · +3905212791 · clinicaltrials_info@chiesi.com
Always discuss trial participation with your own doctor first.
| AUSL Toscana Sud-Est - Ospedale San Donato | Arezzo, Italy | Not Yet Recruiting |
| Azienda Ospedaliera Universitaria Consorziale Policlinico Di Bari | Bari, Italy | Recruiting |
| Irccs Azienda Ospedaliero-Universitaria Di Bologna - Policlinico Di Sant'Orsola | Bologna, Italy | Recruiting |
| A.O. Sant'Anna e San Sebastiano | Caserta, Italy | Not Yet Recruiting |
| U.O.C. Nefrologia ASST Monza - Ospedale San Gerardo | Monza, Italy | Not Yet Recruiting |
| AOU Federico II, Dipartimento di Nefrologia | Naples, Italy | Not Yet Recruiting |
| A.O.U. Policlinico "Giaccone" | Palermo, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07109375